Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Prometheus：快速开发针对新兴病毒威胁的基于人类抗体的治疗和预防方法的平台

• 批准号: 10088385
• 负责人: Kartik Chandran
• 金额: $ 439.05万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-14 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10088385
• 关键词: Academia; Advanced Development; African; Americas; Andes Virus; Antibodies; Antibody Therapy; Blood specimen; Categories; Collaborations; Complement; Crimean-Congo Hemorrhagic Fever Virus; DNA; Data; Development; Disease; Disease Outbreaks; Ebola virus; Engineering; Epitopes; Etiology; Europe; Evaluation; FDA approved; Generations; Goals; Government; Half-Life; Hantavirus; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Human; Immunity; Individual; Industry; Infection; Injections; Lead; Mediating; Modeling; Monoclonal Antibodies; Nairovirus; National Security; Natural Immunity; Pharmaceutical Preparations; Production; Prophylactic treatment; Proteins; Public Health; Recombinants; Research Personnel; Resistance; Risk; Rodent; Rodent Model; Russia; Sin Nombre virus; Survivors; Technology; Therapeutic; Treatment Efficacy; Vaccines; Variant; Viral; Virus; Virus Diseases; Work; World Health Organization; Zaire Ebola virus; Zoonoses; base; cost; efficacy study; high risk; human monoclonal antibodies; in vivo; innovation; natural antibodies; neutralizing monoclonal antibodies; nonhuman primate; pathogenic virus; prophylactic; protective efficacy; public health emergency; side effect; standard of care; success; synergism; therapeutic candidate

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapeutics against two major groups of Category A priority viruses that cause severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). CCHFV, ANDV, and SNV are Category A agents that pose the highest risk to national security and public health. In their latest annual review, the World Health Organization designated CCHF as a Blueprint Priority Disease with the greatest potential to cause a public health emergency. There are no approved vaccines or treatments for any of these agents. The Prometheus CETR, an interwoven collaboration among seven partners from academia, government, and industry organized into two projects and three cores, will accomplish two Grand Goals that are each aimed at delivering a therapeutic product against our target viral pathogens. We will develop and deliver: (1) an antibody-based therapeutic with broad efficacy against CCHFV; and (2) an antibody-based therapeutic with broad efficacy against the hantaviruses ANDV and SNV.

Prometheus CETR 的总体目标是发现和开发基于人类抗体的预防和治疗方法，以对抗引起严重人畜共患疾病的两大类 A 类优先病毒——内罗病毒克里米亚-刚果出血热病毒 (CCHFV) 和安第斯山脉汉坦病毒病毒 (ANDV)、Sin Nombre 病毒 (SNV) 和 Puumula 病毒 (PUUV)、ANDV 和 SNV 属于 A 类病原体。世界卫生组织在最新的年度审查中将 CCHF 指定为最有可能引起公共卫生紧急情况的蓝图优先疾病。目前还没有针对这些疾病的批准疫苗或治疗方法。这些药物是来自学术界、政府和工业界的七个合作伙伴的相互交织的合作，分为两个项目和三个核心，将实现两个宏伟目标，每个目标都旨在提供针对我们的目标病毒病原体的治疗产品。开发和交付： (1) 一种针对 CCHFV 具有广泛功效的基于抗体的治疗方法；以及 (2) 一种针对汉坦病毒 ANDV 和 SNV 具有广泛功效的基于抗体的治疗方法。